Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-CV: Maridebart Cafraglutide for Cardiovascular Outcomes in ASCVD and Overweight/Obesity
NCT07037433Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Countries
- 36
01
Overview
A Phase 3 trial of maridebart cafraglutide in atherosclerotic cardiovascular disease (ASCVD), Overweight, obesity, sponsored by Amgen. Started Jul 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)Overweightobesity
Beyond the preview
Go deeper on NCT07037433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037433.